个人情况介绍、概览

许永，男，博士，研究员。2004年毕业于中科院上海药物化学研究所，获有机化学博士学位。之后在中科院上海有机化学研究所、美国 Van Andel 研究所从事博士后研究。2011年到中科院广州生物医药与健康研究院工作，任课题组长。2012年获中科院“百人计划”择优支持。

目前已在Nature Med、Cell Res、Nat Struct Mol Biol, J Med Chem等杂志发表论文70余篇。主持或参与科技部、中科院、基金委等10余项科研项目。

人才称号、社会兼职等

1.中国科学院“百人计划”

2.广东省生物医药计算重点实验室，副主任

3.广东省高性能计算学会，副理事长

4.广东省药学会药物化学专业委员会，第十一届委员会委员

主要研究方向

研究方向一：分子模拟与药物设计

研究方向二：抗肿瘤靶点发现及先导物发现研究

纵向项目

无

论文

1.Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.Journal of Medicinal Chemistry.2022.共同通讯作者（1/2）.(IF=8.039).中科院1区
2.Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.Journal of Medicinal Chemistry.2022.通讯作者.(IF=8.039).中科院1区
3.Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d] isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.Acta Pharmacologica Sinica.2022.共同通讯作者（1/3）.(IF=7.169).中科院1区
4.Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors.Bioorganic Chemistry.2022.共同通讯作者（1/2）.(IF=5.307).中科院2区
5.Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1- ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.European Journal of Medicinal Chemistry.2022.共同通讯作者（1/2）.(IF=7.088).中科院1区
6.Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.Journal of Medicinal Chemistry.2022.通讯作者.(IF=8.039).中科院1区
7.Discovery and characterization of benzimidazole derivative XY123 as a selective, and orally available RORγ inverse agonist.Journal of Medicinal Chemistry.2021.通讯作者.(IF=8.039).中科院1区
8.Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors.Bioorganic & Medicinal Chemistry.2021.共同通讯作者（1/2）.(IF=3.461).中科院3区
9.Y06014 is a selective BET inhibitor for the treatment of prostate cancer.Acta Pharmacologica Sinica.2021.共同通讯作者（1/3）.(IF=7.169).中科院1区
10.Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities.Bioorganic Chemistry.2020.通讯作者.(IF=5.307).中科院2区

学术成果

无